Agreement combines BioAtla’s Conditionally Active Biologic (CAB) antibodies with Pfizer’s Proprietary ADC Payloads Pfizer gains rights to BioAtla CAB immune checkpoint inhibitors targeting CTLA-4   SAN DIEGO, Dec. 7, 2015 /PRNewswire/ — BioAtla LLC, a biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a […]